RheumPAC is the ACR’s political action committee dedicated to increasing rheumatology’s presence on Capitol Hill. It is the only PAC dedicated to the interests of all rheumatologists and their patients. RheumPAC began in 2007 with the purpose of building contacts, influence and visibility within Washington, D.C. for rheumatology. RheumPAC works to support and elect pro-rheumatology…
Search results for: hospital
The Real Story on RA: Survey Finds Communication Gaps Between Physicians & Patients with RA
Survey results released earlier this year found that communication difficulties exist between patients and their rheumatologists for many reasons—possibly resulting in more disease activity despite advances in RA treatments. Here are tips for communicating with your patients and helping them be more proactive in their care…
Rheumatology Drug Updates: Ixekizumab Improves Work Productivity, plus Vobarilizumab Completes Phase 2 Trial in Rheumatoid Arthritis
Ixekizumab Improves Work Productivity in Patients with Plaque Psoriasis Indirect costs of reduced work productivity can have a significant impact on a patient’s quality of life. A recent article published in JAMA Dermatology analyzed the results of three multicenter, randomized double-blind Phase 3 trials, UNCOVER-1, UNCOVER-2 and UNCOVER-3, which evaluated the effect of ixekizumab on…
Rheumatologist, Sci Fi Fan Dr. Ernie Katler Showcases Star Wars Treasures in Office
When patients enter the rheumatology office of Ernie Katler, MD, FACP, FACR, in San Pablo, Calif., they’re transported to a galaxy far, far away. Hundreds of toys, props and figurines of Yoda, Darth Vader, Jabba the Hutt and other characters, as well as three original Star Wars movie posters, greet patients. If they’re lucky, patients…
Potential Benefits, Pitfalls of Biosimilars Reviewed at EULAR 2016
LONDON—The availability of a biosimilar form of infliximab has dramatically increased the number of Norwegians taking one form or another of the drug, an expert on biosimilars said in a debate-style session at the Annual Congress of the European League Against Rheumatism (EULAR 2016). The expanded uptake of Remicade (infliximab) and its biosimilar, Remsima (international…
Why Rheumatologists Should Ask Patients About Drug Use
SAN FRANCISCO—“We’ve known for a long time that prescription medications and illicit drugs can both mimic and actually induce the autoimmune syndromes treated by rheumatologists,” Jonathan Graf, MD, professor of medicine at the University of California–San Francisco in the Division of Rheumatology at Zuckerberg San Francisco General Hospital (SFGH), said at the California Rheumatology Alliance…
Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing
The use of biosimilars for rheumatology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…
Blacks, Asians at Higher Risk for Allopurinol-Related Skin Reactions
Be careful when prescribing allopurinol to black and Asian gout patients, a study newly advises. Black and Asian patients who take this ubiquitous, more-than-40-year-old medication are at much higher risk of certain serious skin reactions than are Caucasians or Hispanics. Compared with Caucasians, blacks who take allopurinol to lower blood urate levels have an increased…
Chronic Reactive Arthritis Secondary to Intravesical Bacillus Calmette–Guerin in Bladder Carcinoma
A 50-year-old man with history of superficial bladder carcinoma presented to our rheumatology clinic for a three-year history of symmetric polyarthralgias. He had undergone multiple transurethral resection of bladder tumor procedures and bacillus Calmette–Guerin (BCG) treatments. Prior to receiving BCG, he was fully functional and employed. Days after receiving his second BCG treatment, he developed…
Total Joint Arthroplasty Outcome Measures Toolkit Helps Rheumatologists’ Post-Surgical Assessments
Amir Atwal* is a 76-year-old man who had a knee arthroplasty six weeks ago: He wonders how he is doing in comparison to other individuals of his age at the same stage of recovery. Will you be able to provide him with an answer? If you are looking for a one-stop shop to help you…
- « Previous Page
- 1
- …
- 203
- 204
- 205
- 206
- 207
- …
- 323
- Next Page »